Optimizing antifungal drug dosing and monitoring to avoid toxicity and improve outcomes in patients with haematological disorders

Internal Medicine Journal

Volumn 38, Issue 6 B, 2008, Pages 521-537

  Worth, L J ^a   Blyth, C C ^b   Booth, D L ^c   Kong, D C M ^d   Marriott, D ^e,f   Cassumbhoy, M ^a   Ray, J ^e   Slavin, M A ^a,c,g   Wilkes, J R ^h  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b ROYAL NORTH SHORE HOSPITAL   (Australia)

^c ROYAL MELBOURNE HOSPITAL   (Australia)

^d MONASH UNIVERSITY   (Australia)

^e ST VINCENT S HOSPITAL   (Australia)

^f UNIVERSITY OF NEW SOUTH WALES   (Australia)

^g ALFRED HOSPITAL   (Australia)

^h ROYAL PERTH HOSPITAL   (Australia)

Author keywords

Antifungal therapy; Drug interactions; Haematology; Therapeutic drug monitoring (TDM); Toxicity

Indexed keywords

ANTIFUNGAL AGENT; APREPITANT; ATORVASTATIN; BUSULFAN; CIMETIDINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; DEXAMETHASONE; DIAZEPAM; ECHINOCANDIN; FLUCONAZOLE; IFOSFAMIDE; IMATINIB; IRINOTECAN; ITRACONAZOLE; METHYLPREDNISOLONE; MIDAZOLAM; NIFEDIPINE; OMEPRAZOLE; PANTOPRAZOLE; POLYENE ANTIBIOTIC AGENT; POSACONAZOLE; PREDNISOLONE; PYRROLE DERIVATIVE; UNINDEXED DRUG; VORICONAZOLE;

ABDOMINAL PAIN; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLURRED VISION; CHILL; CLINICAL ASSESSMENT; COLOR VISION DEFECT; DIARRHEA; DRUG MONITORING; DRUG WITHDRAWAL; EYE TOXICITY; FEVER; FOOD DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HEADACHE; HEMATOLOGIC DISEASE; HUMAN; HYPERBILIRUBINEMIA; LABORATORY DIAGNOSIS; LIVER TOXICITY; MYCOSIS; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; PHARMACODYNAMICS; PHOTOPHOBIA; PHOTOSENSITIVITY; PRIORITY JOURNAL; PRURITUS; RASH; REVIEW; RIGOR; SIDE EFFECT; SKIN TOXICITY; TREATMENT OUTCOME; VISUAL DISORDER; VOMITING;

ANTIFUNGAL AGENTS; DRUG INTERACTIONS; DRUG MONITORING; HEMATOLOGIC DISEASES; HUMANS; MYCOSES; OPPORTUNISTIC INFECTIONS;

EID: 46149088035     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2008.01726.x     Document Type: Review

References (151)

1. Ghosal A, Hapangama N, Yuan Y, Achanfuo-Yeboah J, Iannucci R, Chowdhury S et al. Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of posaconazole (Noxafil). Drug Metab Dispos 2004 32 : 267 71.
2. Purkins L, Wood N, Ghahramani P, Love ER, Eve MD, Fielding A. Coadministration of voriconazole and phenytoin: pharmacokinetic interaction, safety, and toleration. Br J Clin Pharmacol 2003 56 Suppl 1 : 37 44.
3. Krishna G, Parsons A, Kantesaria B, Mant T. Evaluation of the pharmacokinetics of posaconazole and rifabutin following co-administration to healthy men. Curr Med Res Opin 2007 23 : 545 52.
4. Panomvana Na Ayudhya D., Thanompuangseree N, Tansuphaswadikul S. Effect of rifampicin on the pharmacokinetics of fluconazole in patients with AIDS. Clin Pharmacokinet 2004 43 : 725 32.
5. Chen SC, Sorrell TC. Antifungal agents. Med J Aust 2007 187 : 404 9.
6. Karthaus M, Cornely OA. Second-line treatment in invasive mould infections. Mycoses 2006 49 Suppl 1 : 23 6.
7. Park JY, Kim KA, Shin JG, Lee KY. Effect of ketoconazole on the pharmacokinetics of rosiglitazone in healthy subjects. Br J Clin Pharmacol 2004 58 : 397 402.
8. Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D. Possible interaction between gliclazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia. Br J Clin Pharmacol 2001 52 : 456 7.
9. Hatorp V, Hansen KT, Thomsen MS. Influence of drugs interacting with CYP3A4 on the pharmacokinetics, pharmacodynamics, and safety of the prandial glucose regulator repaglinide. J Clin Pharmacol 2003 43 : 649 60.
10. Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis 2003 36 : 630 7.
11. Owens RC Jr., Nolin TD. Antimicrobial-associated QT interval prolongation: pointes of interest. Clin Infect Dis 2006 43 : 1603 11.
12. Alkan Y, Haefeli WE, Burhenne J, Stein J, Yaniv I, Shalit I. Voriconazole-induced QT interval prolongation and ventricular tachycardia: a non-concentration-dependent adverse effect. Clin Infect Dis 2004 39 : e49 52.
13. Pham CP, de Feiter PW, van der Kuy PH, van Mook WN. Long QTc interval and torsade de pointes caused by fluconazole. Ann Pharmacother 2006 40 : 1456 61.
14. Owens RC Jr. QT prolongation with antimicrobial agents: understanding the significance. Drugs 2004 64 : 1091 124.
15. Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 2000 38 : 41 57.
16. Shimizu T, Ochiai H, Asell F, Shimizu H, Saitoh R, Hama Y et al. Bioinformatics research on inter-racial difference in drug metabolism I. Analysis on frequencies of mutant alleles and poor metabolizers on CYP2D6 and CYP2C19. Drug Metab Pharmacokinet 2003 18 : 48 70.
17. Groll AH, Gea-Banacloche JC, Glasmacher A, Just-Nuebling G, Maschmeyer G, Walsh TJ. Clinical pharmacology of antifungal compounds. Infect Dis Clin North Am 2003 17 : 159 91, ix.
18. Leveque D, Nivoix Y, Jehl F, Herbrecht R. Clinical pharmacokinetics of voriconazole. Int J Antimicrob Agents 2006 27 : 274 84.
19. Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokinet 2000 38 : 111 80.
20. Miners JO, Birkett DJ. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 1998 45 : 525 38.
21. Crussell-Porter LL, Rindone JP, Ford MA, Jaskar DW. Low-dose fluconazole therapy potentiates the hypoprothrombinemic response of warfarin sodium. Arch Intern Med 1993 153 : 102 4.
22. Cadle RM, Zenon GJ 3rd., Rodriguez-Barradas MC, Hamill RJ. Fluconazole-induced symptomatic phenytoin toxicity. Ann Pharmacother 1994 28 : 191 5.
23. Mitra AK, Thummel KE, Kalhorn TF, Kharasch ED, Unadkat JD, Slattery JT. Inhibition of sulfamethoxazole hydroxylamine formation by fluconazole in human liver microsomes and healthy volunteers. Clin Pharmacol Ther 1996 59 : 332 40.
24. Kazierad DJ, Martin DE, Blum RA, Tenero DM, Ilson B, Boike SC et al. Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers. Clin Pharmacol Ther 1997 62 : 417 25.
25. Ringden O, Andstrom E, Remberger M, Svahn BM, Tollemar J. Safety of liposomal amphotericin B (AmBisome) in 187 transplant recipients treated with cyclosporin. Bone Marrow Transpl 1994 14 Suppl 5 : S10 4.
26. Luber AD, Maa L, Lam M, Guglielmo BJ. Risk factors for amphotericin B-induced nephrotoxicity. J Antimicrob Chemother 1999 43 : 267 71.
27. Depont F, Vargas F, Dutronc H, Giauque E, Ragnaud JM, Galperine T et al. Drug-drug interactions with systemic antifungals in clinical practice. Pharmacoepidemiol Drug Saf 2007 16 : 1227 33.
28. Albengres E, Le Louet H, Tillement JP. Systemic antifungal agents. Drug interactions of clinical significance. Drug Saf 1998 18 : 83 97.
29. Cappelletty D, Eiselstein-McKitrick K. The echinocandins. Pharmacotherapy 2007 27 : 369 88.
30. Stone EA, Fung HB, Kirschenbaum HL. Caspofungin: an echinocandin antifungal agent. Clin Ther 2002 24 : 351 77, discussion 29.
31. Wagner C, Graninger W, Presterl E, Joukhadar C. The echinocandins: comparison of their pharmacokinetics, pharmacodynamics and clinical applications. Pharmacology 2006 78 : 161 77.
32. Stone JA, Migoya EM, Hickey L, Winchell GA, Deutsch PJ, Ghosh K et al. Potential for interactions between caspofungin and nelfinavir or rifampin. Antimicrob Agents Chemother 2004 48 : 4306 14.
33. Morris MI, Villmann M. Echinocandins in the management of invasive fungal infections, Part 2. Am J Health Syst Pharm 2006 63 : 1813 20.
34. Cancidas (caspofungin) Australian Approved Product Information. Merck Sharp and Dohme Pty Ltd., 1 April 2005.
35. Lewis RE. Managing drug interactions in the patient with aspergillosis. Med Mycol 2006 44 (Suppl 349 56.
36. Emend (aprepitant) Australian Approved Product Information. Merck Sharp & Dohme, 1 November 2007.
37. Sanchez RI, Wang RW, Newton DJ, Bakhtiar R, Lu P, Chiu SH et al. Cytochrome P450 3A4 is the major enzyme involved in the metabolism of the substance P receptor antagonist aprepitant. Drug Metab Dispos 2004 32 : 1287 92.
38. Kahri J, Valkonen M, Backlund T, Vuoristo M, Kivisto KT. Rhabdomyolysis in a patient receiving atorvastatin and fluconazole. Eur J Clin Pharmacol 2005 60 : 905 7.
39. Kantola T, Backman JT, Niemi M, Kivisto KT, Neuvonen PJ. Effect of fluconazole on plasma fluvastatin and pravastatin concentrations. Eur J Clin Pharmacol 2000 56 : 225 9.
40. Kantola T, Kivisto KT, Neuvonen PJ. Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin Pharmacol Ther 1998 64 : 58 65.
41. Mazzu AL, Lasseter KC, Shamblen EC, Agarwal V, Lettieri J, Sundaresen P. Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin. Clin Pharmacol Ther 2000 68 : 391 400.
42. Vfend (voriconazole) Australian Approved Product Information. Pfizer Pty Ltd., 12 April 2006.
43. Schering-Plough. Noxafil (posaconazole) Australian Approved Product Information, 10 March 2006.
44. Buggia I, Zecca M, Alessandrino EP, Locatelli F, Rosti G, Bosi A et al. Itraconazole can increase systemic exposure to busulfan in patients given bone marrow transplantation. GITMO (Gruppo Italiano Trapianto di Midollo Osseo). Anticancer Res 1996 16 : 2083 8.
45. Sporanox (itraconazole) Approved Product Information. Janssen-Cilag Pty Ltd., 8 February 2006.
46. Lazar JD, Wilner KD. Drug interactions with fluconazole. Rev Infect Dis 1990 12 Suppl 3 : S327 33.
47. Courtney R, Wexler D, Statkevich P, Lim J, Batra V, Laughlin M. Effect of cimetidine on the pharmacokinetics of posaconazole in healthy volunteers. Interscience Conference Antimicrobial Agents Chemotherapy, abstract A-1838, 2002.
48. Cervelli MJ. Fluconazole-sirolimus drug interaction. Transplantation 2002 74 : 1477 8.
49. Boddy AV, Yule SM. Metabolism and pharmacokinetics of oxazaphosphorines. Clin Pharmacokinet 2000 38 : 291 304.
50. Kruger HU, Schuler U, Zimmermann R, Ehninger G. Absence of significant interaction of fluconazole with cyclosporin. J Antimicrob Chemother 1989 24 : 781 6.
51. Gubbins PO, Amsden JR. Drug-drug interactions of antifungal agents and implications for patient care. Expert Opin Pharmacother 2005 6 : 2231 43.
52. Varis T, Kivisto KT, Backman JT, Neuvonen PJ. The cytochrome P450 3A4 inhibitor itraconazole markedly increases the plasma concentrations of dexamethasone and enhances its adrenal-suppressant effect. Clin Pharmacol Ther 2000 68 : 487 94.
53. Lam M, Ignoffo R. A guide to clinically relevant drug interactions in oncology. J Oncol Pharm Pract 2003 9 : 45 85.
54. Novartis. Gleevec (imatinib mesylate) Australian Approved Product Information, 1 November 2007.
55. Lebrun-Vignes B, Archer VC, Diquet B, Levron JC, Chosidow O, Puech AJ et al. Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects. Br J Clin Pharmacol 2001 51 : 443 50.
56. Jaruratanasirikul S, Sriwiriyajan S. Effect of omeprazole on the pharmacokinetics of itraconazole. Eur J Clin Pharmacol 1998 54 : 159 61.
57. Varis T, Kivisto KT, Neuvonen PJ. The effect of itraconazole on the pharmacokinetics and pharmacodynamics of oral prednisolone. Eur J Clin Pharmacol 2000 56 : 57 60.
58. Marty FM, Lowry CM, Cutler CS, Campbell BJ, Fiumara K, Baden LR et al. Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transpl 2006 12 : 552 9.
59. Mathis AS, Shah NK, Friedman GS. Combined use of sirolimus and voriconazole in renal transplantation: a report of two cases. Transpl Proc 2004 36 : 2708 9.
60. Manez R, Martin M, Raman D, Silverman D, Jain A, Warty V et al. Fluconazole therapy in transplant recipients receiving FK506. Transplantation 1994 57 : 1521 3.
61. Chen S, Slavin M, Nguyen Q, Marriott D, Playford EG, Ellis D et al. Active surveillance for candidemia, Australia. Emerg Infect Dis 2006 12 : 1508 16.
62. Marr KA, Hachem R, Papanicolaou G, Somani J, Arduino JM, Lipka CJ et al. Retrospective study of the hepatic safety profile of patients concomitantly treated with caspofungin and cyclosporin A. Transpl Infect Dis 2004 6 : 110 6.
63. Gillies J, Hung KA, Fitzsimons E, Soutar R. Severe vincristine toxicity in combination with itraconazole. Clin Lab Haematol 1998 20 : 123 4.
64. Mantadakis E, Amoiridis G, Kondi A, Kalmanti M. Possible increase of the neurotoxicity of vincristine by the concurrent use of posaconazole in a young adult with leukemia. J Pediatr Hematol Oncol 2007 29 : 130.
65. P Fizer. Diflucan (fluconazole) Australian Approved Product Information, 1 June 2005.
66. Zimmermann T, Yeates RA, Laufen H, Pfaff G, Wildfeuer A. Influence of concomitant food intake on the oral absorption of two triazole antifungal agents, itraconazole and fluconazole. Eur J Clin Pharmacol 1994 46 : 147 50.
67. Barone JA, Moskovitz BL, Guarnieri J, Hassell AE, Colaizzi JL, Bierman RH et al. Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers. Pharmacotherapy 1998 18 : 295 301.
68. Lange D, Pavao JH, Wu J, Klausner M. Effect of a cola beverage on the bioavailability of itraconazole in the presence of H2 blockers. J Clin Pharmacol 1997 37 : 535 40.
69. Gubbins PO, McConnell SA, Gurley BJ, Fincher TK, Franks AM, Williams DK et al. Influence of grapefruit juice on the systemic availability of itraconazole oral solution in healthy adult volunteers. Pharmacotherapy 2004 24 : 460 7.
70. Penzak SR, Gubbins PO, Gurley BJ, Wang PL, Saccente M. Grapefruit juice decreases the systemic availability of itraconazole capsules in healthy volunteers. Ther Drug Monit 1999 21 : 304 9.
71. Baxter K, ed. Stockley's Drug Interactions, 7th edn. London : Pharmaceutical Press 2006.
72. Purkins L, Wood N, Kleinermans D, Greenhalgh K, Nichols D. Effect of food on the pharmacokinetics of multiple-dose oral voriconazole. Br J Clin Pharmacol 2003 56 Suppl 1 : 17 23.
73. Sansone-Parsons A, Krishna G, Calzetta A, Wexler D, Kantesaria B, Rosenberg MA et al. Effect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers. Antimicrob Agents Chemother 2006 50 : 1881 3.
74. Courtney R, Wexler D, Radwanski E, Lim J, Laughlin M. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br J Clin Pharmacol 2004 57 : 218 22.
75. Deray G. Amphotericin B nephrotoxicity. J Antimicrob Chemother 2002 49 Suppl 1 : 37 41.
76. Fisher MA, Talbot GH, Maislin G, McKeon BP, Tynan KP, Strom BL. Risk factors for Amphotericin B-associated nephrotoxicity. Am J Med 1989 87 : 547 52.
77. Johansen H, Gotzsche P. Amphotericin B lipid soluble formulations vs amphotericin B in cancer patients with neutropenia. Cochrane Database Syst Rev 2000 3 : CD000969.
78. Barrett JP, Vardulaki KA, Conlon C, Cooke J, Daza-Ramirez P, Evans EG et al. A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations. Clin Ther 2003 25 : 1295 320.
79. Girois SB, Chapuis F, Decullier E, Revol BG. Adverse effects of antifungal therapies in invasive fungal infections: review and meta-analysis. Eur J Clin Microbiol Infect Dis 2006 25 : 138 49.
80. Walsh TJ, Hiemenz JW, Seibel NL, Perfect JR, Horwith G, Lee L et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998 26 : 1383 96.
81. Anaissie EJ, Mattiuzzi GN, Miller CB, Noskin GA, Gurwith MJ, Mamelok RD et al. Treatment of invasive fungal infections in renally impaired patients with amphotericin B colloidal dispersion. Antimicrob Agents Chemother 1998 42 : 606 11.
82. Winston DJ, Hathorn JW, Schuster MG, Schiller GJ, Territo MC. A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer. Am J Med 2000 108 : 282 9.
83. Walsh TJ, Pappas P, Winston DJ, Lazarus HM, Petersen F, Raffalli J et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002 346 : 225 34.
84. Walsh TJ, Teppler H, Donowitz GR, Maertens JA, Baden LR, Dmoszynska A et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004 351 : 1391 402.
85. Boogaerts M, Winston DJ, Bow EJ, Garber G, Reboli AC, Schwarer AP et al. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial. Ann Intern Med 2001 135 : 412 22.
86. Rex JH, Bennett JE, Sugar AM, Pappas PG, van der Horst CM, Edwards JE et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med 1994 331 : 1325 30.
87. Kullberg BJ, Sobel JD, Ruhnke M, Pappas PG, Viscoli C, Rex JH et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 2005 366 : 1435 42.
88. Mora-Duarte J, Betts R, Rotstein C, Colombo AL, Thompson-Moya L, Smietana J et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002 347 : 2020 9.
89. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002 347 : 408 15.
90. Wingard JR, Kubilis P, Lee L, Yee G, White M, Walshe L et al. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis 1999 29 : 1402 7.
91. Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, Bodensteiner D et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999 340 : 764 71.
92. Bates DW, Su L, Yu DT, Chertow GM, Seger DL, Gomes DR et al. Correlates of acute renal failure in patients receiving parenteral amphotericin B. Kidney Int 2001 60 : 1452 9.
93. Holler B, Omar SA, Farid MD, Patterson MJ. Effects of fluid and electrolyte management on amphotericin B-induced nephrotoxicity among extremely low birth weight infants. Pediatrics 2004 113 : e608 16.
94. Llanos A, Cieza J, Bernardo J, Echevarria J, Biaggioni I, Sabra R et al. Effect of salt supplementation on amphotericin B nephrotoxicity. Kidney Int 1991 40 : 302 8.
95. Stein RS, Alexander JA. Sodium protects against nephrotoxicity in patients receiving amphotericin B. Am J Med Sci 1989 298 : 299 304.
96. Mayer J, Doubek M, Doubek J, Horky D, Scheer P, Stepanek M. Reduced nephrotoxicity of conventional amphotericin B therapy after minimal nephroprotective measures: animal experiments and clinical study. J Infect Dis 2002 186 : 379 88.
97. Grasela TH Jr., Goodwin SD, Walawander MK, Cramer RL, Fuhs DW, Moriarty VP. Prospective surveillance of intravenous amphotericin B use patterns. Pharmacotherapy 1990 10 : 341 8.
98. Goodwin SD, Cleary JD, Walawander CA, Taylor JW, Grasela TH Jr. Pretreatment regimens for adverse events related to infusion of amphotericin B. Clin Infect Dis 1995 20 : 755 61.
99. Wingard JR, White MH, Anaissie E, Raffalli J, Goodman J, Arrieta A. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clin Infect Dis 2000 31 : 1155 63.
100. Pathak A, Pien FD, Carvalho L. Amphotericin B use in a community hospital, with special emphasis on side effects. Clin Infect Dis 1998 26 : 334 8.
101. Eriksson U, Seifert B, Schaffner A. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial. BMJ 2001 322 : 579 82.
102. Peleg AY, Woods ML. Continuous and 4 h infusion of amphotericin B: a comparative study involving high-risk haematology patients. J Antimicrob Chemother 2004 54 : 803 8.
103. Groll AH, Kolve H. Antifungal agents: in vitro susceptibility testing, pharmacodynamics, and prospects for combination therapy. Eur J Clin Microbiol Infect Dis 2004 23 : 256 70.
104. Prentice HG, Hann IM, Herbrecht R, Aoun M, Kvaloy S, Catovsky D et al. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol 1997 98 : 711 8.
105. Subira M, Martino R, Gomez L, Marti JM, Estany C, Sierra J. Low-dose amphotericin B lipid complex vs. conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies - a randomized, controlled trial. Eur J Haematol 2004 72 : 342 7.
106. Malik IA, Moid I, Aziz Z, Khan S, Suleman M. A randomized comparison of fluconazole with amphotericin B as empiric anti-fungal agents in cancer patients with prolonged fever and neutropenia. Am J Med 1998 105 : 478 83.
107. Villanueva A, Arathoon EG, Gotuzzo E, Berman RS, DiNubile MJ, Sable CA. A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin Infect Dis 2001 33 : 1529 35.
108. Villanueva A, Gotuzzo E, Arathoon EG, Noriega LM, Kartsonis NA, Lupinacci RJ et al. A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am J Med 2002 113 : 294 9.
109. Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007 356 : 348 59.
110. Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007 356 : 335 47.
111. Winston DJ, Maziarz RT, Chandrasekar PH, Lazarus HM, Goldman M, Blumer JL et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med 2003 138 : 705 13.
112. Marr KA, Crippa F, Leisenring W, Hoyle M, Boeckh M, Balajee SA et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 2004 103 : 1527 33.
113. Oude Lashof AM, De Bock R, Herbrecht R, de Pauw BE, Krcmery V, Aoun M et al. An open multicentre comparative study of the efficacy, safety and tolerance of fluconazole and itraconazole in the treatment of cancer patients with oropharyngeal candidiasis. Eur J Cancer 2004 40 : 1314 9.
114. Bowden R, Chandrasekar P, White MH, Li X, Pietrelli L, Gurwith M et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 2002 35 : 359 66.
115. White MH, Bowden RA, Sandler ES, Graham ML, Noskin GA, Wingard JR et al. Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis 1998 27 : 296 302.
116. Smith SR, Galloway MJ, Reilly JT, Davies JM. Amiloride prevents amphotericin B related hypokalaemia in neutropenic patients. J Clin Pathol 1988 41 : 494 7.
117. MacGregor RR, Bennett JE, Erslev AJ. Erythropoietin concentration in amphotericin B-induced anemia. Antimicrob Agents Chemother 1978 14 : 270 3.
118. Yeo EJ, Ryu JH, Cho YS, Chun YS, Huang LE, Kim MS et al. Amphotericin B blunts erythropoietin response to hypoxia by reinforcing FIH-mediated repression of HIF-1. Blood 2006 107 : 916 23.
119. Anaissie EJ, Vartivarian SE, Abi-Said D, Uzun O, Pinczowski H, Kontoyiannis DP et al. Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: a matched cohort study. Am J Med 1996 101 : 170 6.
120. Novelli V, Holzel H. Safety and tolerability of fluconazole in children. Antimicrob Agents Chemother 1999 43 : 1955 60.
121. Rex JH, Pappas PG, Karchmer AW, Sobel J, Edwards JE, Hadley S et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis 2003 36 : 1221 8.
122. Viscoli C, Castagnola E, Van Lint MT, Moroni C, Garaventa A, Rossi MR et al. Fluconazole versus amphotericin B as empirical antifungal therapy of unexplained fever in granulocytopenic cancer patients: a pragmatic, multicentre, prospective and randomised clinical trial. Eur J Cancer 1996 32A : 814 20.
123. Denning DW, Lee JY, Hostetler JS, Pappas P, Kauffman CA, Dewsnup DH et al. NIAID mycoses study group multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am J Med 1994 97 : 135 44.
124. Menichetti F, Del Favero A, Martino P, Bucaneve G, Micozzi A, Girmenia C et al. Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche dell' Adulto. Clin Infect Dis 1999 28 : 250 5.
125. Glasmacher A, von Lilienfeld-Toal M, Schulte S, Hahn C, Schmidt-Wolf IG, Prentice A. An evidence-based evaluation of important aspects of empirical antibiotic therapy in febrile neutropenic patients. Clin Microbiol Infect 2005 11 Suppl 5 : 17 23.
126. Perfect JR, Marr KA, Walsh TJ, Greenberg RN, DuPont B, de la Torre-Cisneros J et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003 36 : 1122 31.
127. Denning DW, Ribaud P, Milpied N, Caillot D, Herbrecht R, Thiel E et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002 34 : 563 71.
128. Briefing document for voriconazole (oral and intravenous formulation). FDA Antiviral Drugs Advisory Committee. 4 October, 2001. [cited 2007 Nov 21]; Available from URL: http://www.fda.gov/ohrms/dockets/AC/01/briefing/ 3792b201pfizer.pdf
129. Walsh TJ, Raad I, Patterson TF, Chandrasekar P, Donowitz GR, Graybill R et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007 44 : 2 12.
130. Ullmann AJ, Cornely OA, Burchardt A, Hachem R, Kontoyiannis DP, Topelt K et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother 2006 50 : 658 66.
131. Skiest DJ, Vazquez JA, Anstead GM, Graybill JR, Reynes J, Ward D et al. Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection. Clin Infect Dis 2007 44 : 607 14.
132. Raad II, Graybill JR, Bustamante AB, Cornely OA, Gaona-Flores V, Afif C et al. Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin Infect Dis 2006 42 : 1726 34.
133. Maertens J, Raad I, Petrikkos G, Boogaerts M, Selleslag D, Petersen FB et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004 39 : 1563 71.
134. Groll AH, Attarbaschi A, Schuster FR, Herzog N, Grigull L, Dworzak MN et al. Treatment with caspofungin in immunocompromised paediatric patients: a multicentre survey. J Antimicrob Chemother 2006 57 : 527 35.
135. Sanz-Rodriguez C, Lopez-Duarte M, Jurado M, Lopez J, Arranz R, Cisneros JM et al. Safety of the concomitant use of caspofungin and cyclosporin A in patients with invasive fungal infections. Bone Marrow Transpl 2004 34 : 13 20.
136. Vermes A, Guchelaar HJ, Dankert J. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J Antimicrob Chemother 2000 46 : 171 9.
137. Vermes A, van Der Sijs H, Guchelaar HJ. Flucytosine: correlation between toxicity and pharmacokinetic parameters. Chemotherapy 2000 46 : 86 94.
138. Stamm AM, Diasio RB, Dismukes WE, Shadomy S, Cloud GA, Bowles CA et al. Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis. Am J Med 1987 83 : 236 42.
139. Smith J, Safdar N, Knasinski V, Simmons W, Bhavnani SM, Ambrose PG et al. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 2006 50 : 1570 2.
140. Boogaerts MA, Verhoef GE, Zachee P, Demuynck H, Verbist L, De Beule K. Antifungal prophylaxis with itraconazole in prolonged neutropenia: correlation with plasma levels. Mycoses 1989 32 Suppl 1 : 103 8.
141. Glasmacher A, Hahn C, Leutner C, Molitor E, Wardelmann E, Losem C et al. Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole. Mycoses 1999 42 : 443 51.
142. Summers KK, Hardin TC, Gore SJ, Graybill JR. Therapeutic drug monitoring of systemic antifungal therapy. J Antimicrob Chemother 1997 40 : 753 64.
143. Anaissie EJ, Kontoyiannis DP, Huls C, Vartivarian SE, Karl C, Prince RA et al. Safety, plasma concentrations, and efficacy of high-dose fluconazole in invasive mould infections. J Infect Dis 1995 172 : 599 602.
144. Muller C, Arndt M, Queckenberg C, Cornely OA, Theisohn M. HPLC analysis of the antifungal agent posaconazole in patients with haematological diseases. Mycoses 2006 49 Suppl 1 : 17 22.
145. Lyman CA, Walsh TJ. Systemically administered antifungal agents. A review of their clinical pharmacology and therapeutic applications. Drugs 1992 44 : 9 35.
146. Willems L, van der Geest R, de Beule K. Itraconazole oral solution and intravenous formulations: a review of pharmacokinetics and pharmacodynamics. J Clin Pharm Ther 2001 26 : 159 69.
147. Potter M. Strategies for managing systemic fungal infection and the place of itraconazole. J Antimicrob Chemother 2005 56 Suppl 1 : i49 54.
148. Purkins L, Wood N, Ghahramani P, Greenhalgh K, Allen MJ, Kleinermans D. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob Agents Chemother 2002 46 : 2546 53.
149. Trifilio S, Ortiz R, Pennick G, Verma A, Pi J, Stosor V et al. Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transpl 2005 35 : 509 13.
150. Trifilio S, Pennick G, Pi J, Zook J, Golf M, Kaniecki K et al. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer 2007 109 : 1532 5.
151. Pascual AA, Bolay S, Marchetti O. Documentation of Low Voriconazole Blood Levels Followed by Dose Adjustment in Patients with Invasive Fungal Infections not Responding to Therapy (M-1304). 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 27-30 Sep 2006; San Francisco 2006.